NEW YORK, NY / ACCESSWIRE / December 6, 2017 / U.S. markets slumped Tuesday as the recent sell of technology stocks continued. The Dow Jones Industrial Average declined 0.45 percent to close at 24,180.64, while the S&P 500 Index fell 0.37 percent to close at 2,629.57. The Nasdaq Composite Index decreased 0.19 percent to close at 6,762.21. Both the S&P 500 and Nasdaq have posted a three-day losing streak, the first for the S&P 500 since August.
"The Nasdaq Composite Index was getting a little frothy, so it’s not surprising to see that some details in the proposed tax bill that would impact tech companies turned out to be a catalyst for a selloff in these stocks over the past few sessions," said Quincy Krosby, chief market strategist at Prudential Financial.
RDI Initiates Coverage on:
ACADIA Pharmaceuticals Inc.
Moleculin Biotech, Inc.
ACADIA Pharmaceuticals stock moved 3.56% higher Tuesday, to close the day at $29.95. The stock recorded a trading volume of 2,047,729 shares, which was above its three months average volume of 1,504,726 shares. In the last year, ACADIA Pharmaceuticals shares have traded in a range of 24.31 - 41.20. The share price has gained 23.20% from its 52-week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $31.65 is greater than its 200-day moving average of $31.53. Shares of ACADIA Pharmaceuticals have fallen roughly 16.46 percent in the past month and are up 3.85 percent year-to-date.
Access RDI's ACADIA Pharmaceuticals Inc. Research Report at:
On Tuesday, shares in Moleculin Biotech, Inc. recorded a trading volume of 7,314,839 shares, which was above the three months average volume of 415,057 shares. The stock ended the day 14.29% higher at 2.08. The share price has gained 192.96% from its 52-week low with a 52-week trading range of 0.71 - 3.60.The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $1.83 is below its 200-day moving average of $1.94. Shares of Moleculin Biotech have gained roughly 10.64 percent in the past month and are down 8.77 percent year-to-date.
Access RDI's Moleculin Biotech, Inc. Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.